Mesoblast (MESO) reported Sunday a 66% jump in Ryoncil gross sales to $21.9 million in fiscal Q2 compared with the previous quarter, driven by increased physician adoption and broader reimbursement from both commercial and government payers.
Revenue from cell therapy products rose to $20.6 million for the quarter ended Sept. 30, up from $12.9 million in the prior quarter.
The company said it also entered into agreements to issue up to $50 million in unsecured convertible notes at its discretion, pending shareholder approval, to reduce existing debt and support working capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.